サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541790

前立腺肥大症治療市場レポート：治療タイプ別、地域別、2024～2032年

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type (Drug Class, Minimally Invasive Surgeries, Laser Therapy, and Others), and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 148 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
前立腺肥大症治療市場レポート：治療タイプ別、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 148 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の前立腺肥大症治療市場規模は2023年に119億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに181億米ドルに達し、2024～2032年の間に4.6％の成長率（CAGR）を示すと予測しています。

前立腺肥大症（BPH）または良性前立腺肥大症は、尿道の閉塞を引き起こす前立腺の非がん性肥大を指します。この状態は、尿閉、膀胱結石、尿過多による失禁、膀胱の過敏性亢進、尿路感染などを引き起こします。BPHの治療法として一般的に用いられているものには、処方薬、積極的観察療法、単剤・併用療法、植物療法、低侵襲手術（MI）、侵襲的手術などがあります。これらの手術は通常、切除鏡、ラジオ波焼灼装置、泌尿器科用レーザー、前立腺ステント、インプラントなどの装置を用いて行われます。

世界中で泌尿器疾患の有病率が増加していることは、同市場に明るい展望をもたらす重要な要因の一つです。さらに、このような重大な病気にかかりやすい高齢者人口が増加していることも、市場の成長を後押ししています。医療プロバイダーは、前立腺の筋肉を弛緩させ、患者の血圧をコントロールすることによってBPHを管理するためにα遮断薬を使用します。これに伴い、利用可能な治療法に関する大衆の健康意識と意識の高まりも市場成長に寄与しています。さらに、効果的な治療法としての経尿道的前立腺切除術（TURP）の開発など、さまざまな進歩も成長を促す要因として作用しています。TURPは内視鏡的電気外科処置であり、前立腺の一部を切除して異常増殖による閉塞を軽減します。その他の要因としては、個人の医療支出能力の上昇、特に新興諸国における医療インフラの大幅な改善などがあり、市場をさらに牽引すると予想されます。

本レポートで扱う主要質問

  • 世界の前立腺肥大症治療市場はこれまでどのように推移し、今後どのように推移するのか？
  • COVID-19は世界の前立腺肥大症治療市場にどのような影響を与えたか？
  • 主要地域市場とは？
  • 治療タイプ別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界の前立腺肥大症治療市場の構造と主要参入企業は？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の前立腺肥大症治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療タイプ別

  • 薬剤クラス
    • 市場動向
    • 主要タイプ
      • アルファ遮断薬
      • 5-α-還元酵素阻害剤（5-ARI）
      • ホスホジエステラーゼ5酵素阻害剤
      • その他
    • 市場予測
  • 低侵襲手術
    • 市場動向
    • 主要タイプ
      • 経尿道的前立腺切除術（TURP）
      • 経尿道的前立腺切開術（TUIP）
      • 経尿道マイクロ波温熱療法（TUMT）
      • ロボット手術
      • 前立腺尿道リフト
      • その他
    • 市場予測
  • レーザー治療
  • その他

第7章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第8章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第9章 バリューチェーン分析

第10章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第11章 価格分析

第12章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Allergan plc（AbbVie Inc.）
    • Asahi Kasei Corporation
    • Astellas Pharma Inc.
    • Boehringer Ingelheim GmbH（C.H. Boehringer Sohn AG & Ko. KG）
    • Boston Scientific Corporation
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Benign Prostatic Hyperplasia Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Treatment Type (in %), 2023
  • Figure 4: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Region (in %), 2023
  • Figure 5: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 6: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 7: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 8: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: North America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: North America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: United States: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: United States: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Canada: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Canada: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: China: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: China: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Japan: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Japan: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: India: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: India: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: South Korea: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: South Korea: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Australia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Australia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Indonesia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Indonesia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Europe: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Europe: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Germany: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Germany: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: France: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: France: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: United Kingdom: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: United Kingdom: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Italy: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Italy: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Spain: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Spain: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Russia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Russia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Latin America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Latin America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Brazil: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Brazil: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Mexico: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Mexico: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Country (in %), 2023
  • Figure 62: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Global: Benign Prostatic Hyperplasia Treatment Industry: SWOT Analysis
  • Figure 64: Global: Benign Prostatic Hyperplasia Treatment Industry: Value Chain Analysis
  • Figure 65: Global: Benign Prostatic Hyperplasia Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Benign Prostatic Hyperplasia Treatment Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 3: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 4: Global: Benign Prostatic Hyperplasia Treatment Market: Competitive Structure
  • Table 5: Global: Benign Prostatic Hyperplasia Treatment Market: Key Players
目次
Product Code: SR112024A2898

The global benign prostatic hyperplasia treatment market size reached US$ 11.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.1 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.

Benign prostatic hyperplasia (BPH) or benign prostatic hypertrophy refers to the non-cancerous enlargement of the prostate gland that causes blockage in the urethra. This condition causes difficulties in urine retention, bladder stones, incontinence due to overfilling, increased sensitivity of the bladder and infections in the urinary tract. Some of the commonly used treatment alternatives for BPH include prescription drugs, active observation or surveillance, mono drug and combined therapies, phytotherapies and minimally invasive (MI) and invasive surgeries. These surgeries are usually conducted through devices, such as resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents and implants.

The increasing prevalence of urological disorders across the globe represents one of the key factors creating a positive outlook for the market. Furthermore, the rising geriatric population, which is more susceptible to such critical ailments, is providing a boost to the market growth. Healthcare providers use alpha-blockers to manage BPH by relaxing the prostate muscles and controlling the blood pressure of the patient. In line with this, rising health consciousness and awareness among the masses regarding the available treatment alternatives are also contributing to the market growth. Additionally, various advancements, such as the development of transurethral resection of the prostate (TURP) as an effective treatment procedure, are acting as other growth-inducing factors. TURP is an endoscopic electrosurgical procedure that involves removing a portion of the prostate gland to reduce obstruction caused by the abnormal growth. Other factors, including rising healthcare expenditure capacities of individuals, along with significant improvements in the healthcare infrastructure, especially in the developing countries, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global benign prostatic hyperplasia treatment market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type.

Breakup by Treatment Type:

Drug Class

Alpha-Blockers

5-Alpha-reductase Inhibitors (5-ARIs)

Phosphodiesterase-5 Enzyme Inhibitors

Others

Minimally Invasive Surgeries

Transurethral Resection of the Prostate (TURP)

Transurethral Incision of the Prostate (TUIP)

Transurethral Microwave Thermotherapy (TUMT)

Robotic Surgeries

Prostatic Urethral Lifts

Others

Laser Therapy

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global benign prostatic hyperplasia treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global benign prostatic hyperplasia treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the treatment type?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global benign prostatic hyperplasia treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Benign Prostatic Hyperplasia Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Drug Class
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Alpha-Blockers
      • 6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs)
      • 6.1.2.3 Phosphodiesterase-5 Enzyme Inhibitors
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Minimally Invasive Surgeries
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Transurethral Resection of the Prostate (TURP)
      • 6.2.2.2 Transurethral Incision of the Prostate (TUIP)
      • 6.2.2.3 Transurethral Microwave Thermotherapy (TUMT)
      • 6.2.2.4 Robotic Surgeries
      • 6.2.2.5 Prostatic Urethral Lifts
      • 6.2.2.6 Others
    • 6.2.3 Market Forecast
  • 6.3 Laser Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 United States
      • 7.1.1.1 Market Trends
      • 7.1.1.2 Market Forecast
    • 7.1.2 Canada
      • 7.1.2.1 Market Trends
      • 7.1.2.2 Market Forecast
  • 7.2 Asia Pacific
    • 7.2.1 China
      • 7.2.1.1 Market Trends
      • 7.2.1.2 Market Forecast
    • 7.2.2 Japan
      • 7.2.2.1 Market Trends
      • 7.2.2.2 Market Forecast
    • 7.2.3 India
      • 7.2.3.1 Market Trends
      • 7.2.3.2 Market Forecast
    • 7.2.4 South Korea
      • 7.2.4.1 Market Trends
      • 7.2.4.2 Market Forecast
    • 7.2.5 Australia
      • 7.2.5.1 Market Trends
      • 7.2.5.2 Market Forecast
    • 7.2.6 Indonesia
      • 7.2.6.1 Market Trends
      • 7.2.6.2 Market Forecast
    • 7.2.7 Others
      • 7.2.7.1 Market Trends
      • 7.2.7.2 Market Forecast
  • 7.3 Europe
    • 7.3.1 Germany
      • 7.3.1.1 Market Trends
      • 7.3.1.2 Market Forecast
    • 7.3.2 France
      • 7.3.2.1 Market Trends
      • 7.3.2.2 Market Forecast
    • 7.3.3 United Kingdom
      • 7.3.3.1 Market Trends
      • 7.3.3.2 Market Forecast
    • 7.3.4 Italy
      • 7.3.4.1 Market Trends
      • 7.3.4.2 Market Forecast
    • 7.3.5 Spain
      • 7.3.5.1 Market Trends
      • 7.3.5.2 Market Forecast
    • 7.3.6 Russia
      • 7.3.6.1 Market Trends
      • 7.3.6.2 Market Forecast
    • 7.3.7 Others
      • 7.3.7.1 Market Trends
      • 7.3.7.2 Market Forecast
  • 7.4 Latin America
    • 7.4.1 Brazil
      • 7.4.1.1 Market Trends
      • 7.4.1.2 Market Forecast
    • 7.4.2 Mexico
      • 7.4.2.1 Market Trends
      • 7.4.2.2 Market Forecast
    • 7.4.3 Others
      • 7.4.3.1 Market Trends
      • 7.4.3.2 Market Forecast
  • 7.5 Middle East and Africa
    • 7.5.1 Market Trends
    • 7.5.2 Market Breakup by Country
    • 7.5.3 Market Forecast

8 SWOT Analysis

  • 8.1 Overview
  • 8.2 Strengths
  • 8.3 Weaknesses
  • 8.4 Opportunities
  • 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

  • 10.1 Overview
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Degree of Competition
  • 10.5 Threat of New Entrants
  • 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

  • 12.1 Market Structure
  • 12.2 Key Players
  • 12.3 Profiles of Key Players
    • 12.3.1 Abbott Laboratories
      • 12.3.1.1 Company Overview
      • 12.3.1.2 Product Portfolio
      • 12.3.1.3 Financials
      • 12.3.1.4 SWOT Analysis
    • 12.3.2 Allergan plc (AbbVie Inc.)
      • 12.3.2.1 Company Overview
      • 12.3.2.2 Product Portfolio
      • 12.3.2.3 Financials
      • 12.3.2.4 SWOT Analysis
    • 12.3.3 Asahi Kasei Corporation
      • 12.3.3.1 Company Overview
      • 12.3.3.2 Product Portfolio
      • 12.3.3.3 Financials
      • 12.3.3.4 SWOT Analysis
    • 12.3.4 Astellas Pharma Inc.
      • 12.3.4.1 Company Overview
      • 12.3.4.2 Product Portfolio
      • 12.3.4.3 Financials
      • 12.3.4.4 SWOT Analysis
    • 12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
      • 12.3.5.1 Company Overview
      • 12.3.5.2 Product Portfolio
      • 12.3.5.3 SWOT Analysis
    • 12.3.6 Boston Scientific Corporation
      • 12.3.6.1 Company Overview
      • 12.3.6.2 Product Portfolio
      • 12.3.6.3 Financials
      • 12.3.6.4 SWOT Analysis
    • 12.3.7 GlaxoSmithKline Plc
      • 12.3.7.1 Company Overview
      • 12.3.7.2 Product Portfolio
      • 12.3.7.3 Financials
      • 12.3.7.4 SWOT Analysis
    • 12.3.8 Pfizer Inc.
      • 12.3.8.1 Company Overview
      • 12.3.8.2 Product Portfolio
      • 12.3.8.3 Financials
      • 12.3.8.4 SWOT Analysis
    • 12.3.9 Sanofi S.A.
      • 12.3.9.1 Company Overview
      • 12.3.9.2 Product Portfolio
      • 12.3.9.3 Financials
      • 12.3.9.4 SWOT Analysis
    • 12.3.10 Teva Pharmaceutical Industries Ltd.
      • 12.3.10.1 Company Overview
      • 12.3.10.2 Product Portfolio
      • 12.3.10.3 Financials
      • 12.3.10.4 SWOT Analysis